10 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $294M | $367M | 93.3% | 42.6% | — | $53M | $41M |
| 2024 | $179M | $17M | 89.6% | 13.5% | — | $60M | $57M |
| 2023 | $117M | -$25M | 93.9% | -17.5% | — | $60M | $33M |
| 2022 | $120M | -$59M | 98.5% | -46.2% | -$74M | $40M | $24M |
| 2021 | $149M | -$18M | 99.3% | -8.4% | $5M | $20M | $19M |
| 2020 | $109M | -$30M | 99.2% | -26.7% | -$53M | $20M | $30M |
| 2019 | $59M | -$67M | 98.5% | -116.5% | -$43M | $10M | $23M |
| 2018 | $45M | — | 99.4% | -163.3% | -$60M | — | $76M |
| 2017 | $4M | — | 0.0% | -1775.6% | -$78M | — | $38M |
| 2016 | $20M | — | 0.0% | -342.2% | -$77M | — | $18M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $59M | $9M | 92.2% | 20.2% | — | $45M | $24M |
| Dec '25 | $70M | $268M | 91.5% | 33.2% | — | $53M | $41M |
| Sep '25 | $69M | $28M | 93.2% | 40.9% | — | $60M | $49M |
| Jun '25 | $102M | $60M | 95.6% | 60.1% | — | $60M | $53M |
| Mar '25 | $53M | $11M | 91.7% | 23.9% | — | $60M | $46M |
| Dec '24 | $58M | $14M | 89.9% | 28.9% | — | $60M | $57M |
| Sep '24 | $55M | $12M | 85.5% | 25.4% | — | $60M | $52M |
| Jun '24 | $37M | -$1M | 92.4% | 1.2% | — | $60M | $36M |
| Mar '24 | $30M | -$8M | 93.1% | -23.6% | — | $60M | $26M |
| Dec '23 | $36M | $737000 | 89.4% | 5.5% | — | $60M | $33M |
| Sep '23 | $28M | -$6M | 95.5% | -15.9% | — | $60M | $45M |
| Jun '23 | $27M | -$7M | 96.0% | -19.6% | — | $60M | $49M |
| Mar '23 | $26M | -$14M | 96.3% | -48.8% | — | $60M | $40M |
| Dec '22 | $51M | $1M | 99.3% | 4.1% | -$22M | $40M | $24M |
| Sep '22 | $22M | -$19M | 98.9% | -82.1% | -$13M | $40M | $30M |
| Jun '22 | $30M | -$13M | 96.5% | -43.5% | -$13M | $30M | $27M |
| Mar '22 | $17M | -$27M | 99.3% | -156.9% | -$26M | $30M | $25M |
| Dec '21 | $20M | -$23M | 97.6% | -104.9% | -$19M | $20M | $19M |
| Sep '21 | $22M | -$21M | 99.3% | -91.8% | -$10M | $20M | $30M |
| Jun '21 | $26M | -$14M | 99.5% | -49.7% | $55M | $20M | $85M |
How the market has priced RIGL against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Rigel Pharmaceuticals Inc's revenue has grown 22.1% per year. These are computed facts, not advice.
As of FY2025, Rigel Pharmaceuticals Inc reported $53M of total debt against $41M of cash; operating income covered interest expense 17×.
In FY2025, gross margin was 93.3%, operating margin 42.6%, and net margin 124.7%.
As of Jun '26, Rigel Pharmaceuticals Inc traded at a price-to-earnings ratio of about 1.9× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.